- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorization from the European Commission for Zefylti®, a filgrastim biosimilar. This development follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency in December 2024, indicating strong support for the product's safety and efficacy. The approval opens up market opportunities in the EU, potentially enhancing Aurobindo's growth trajectory in the biologics segment and reducing reliance on existing product lines. Investors should monitor this development as it may significantly influence the company's revenues and position in the competitive biopharmaceutical market.